LOS ANGELES, May 26, 2024 (GLOBE NEWSWIRE) The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Blueprint Medicines Corporation
Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Equities researchers at Zacks Research issued their Q2 2024 earnings per share estimates for shares of Blueprint Medicines in a report released on Tuesday, May 14th. Zacks Research analyst A. Chakraborty forecasts that the biotechnology company will earn ($1.40) per share for the quarter. The consensus estimate […]
Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Analysts at Zacks Research issued their Q2 2024 earnings per share estimates for Blueprint Medicines in a report released on Tuesday, May 14th. Zacks Research analyst A. Chakraborty anticipates that the biotechnology company will post earnings of ($1.40) per share for the quarter. The consensus estimate for […]
Stephens assumed coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report published on Tuesday, MarketBeat.com reports. The firm issued an overweight rating and a $140.00 price objective on the biotechnology company’s stock. Other equities analysts have also issued research reports about the company. SVB Leerink raised Blueprint Medicines from an underperform […]